SCHEMBL750971

SCHEMBL750971

O=C(O)C1CC2(CCCO2)CN1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.43
CYP1A2 P05177 2/20 0.43
GRM2 Q14416 1/20 0.43
GRM3 Q14832 1/20 0.43
CYP2D6 P10635 3/20 0.30
LMNA P02545 3/20 0.30
BLM P54132 3/20 0.30
MEN1 O00255 2/20 0.30
THRB P10828 2/20 0.30
KMT2A Q03164 2/20 0.30
TSHR P16473 1/20 0.30
CYP2C19 P33261 1/20 0.30
RAB9A P51151 1/20 0.30
PMP22 Q01453 1/20 0.30
OPRK1 P41145 3/20 0.30
KDM4E B2RXH2 1/20 0.30
MTOR P42345 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
OPRM1 P35372 1/20 0.30
OPRD1 P41143 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25367647 0.91 CYP1A2 (0.47) ALOX15CYP1A2GRM2GRM3CYP2D6
SCHEMBL26114592 0.85 GRM2 (0.32) ALOX15CYP1A2GRM2GRM3
SCHEMBL11212499 0.83 GRM2 (0.41) ALOX15CYP1A2GRM2GRM3
SCHEMBL27113627 0.81 BACE1 (0.39) KMT2A
SCHEMBL31375024 0.76 BACE1 (0.38) KMT2A
SCHEMBL31375037 0.76 BACE1 (0.38) KMT2A
SCHEMBL6120873 0.76 CYP1A2 (0.43) ALOX15CYP1A2GRM2GRM3CYP2D6
SCHEMBL11212501 0.75 CYP1A2 (0.46) ALOX15CYP1A2GRM2GRM3CYP2D6
SCHEMBL30148928 0.72 CYP2C19 (0.44) ALOX15CYP1A2GRM2GRM3CYP2D6
SCHEMBL7380804 0.71 CYP1A2 (0.48) ALOX15CYP1A2GRM2GRM3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
EP-2430014-A1 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2012-03-21 EP disclosed
WO-2011050146-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2011-04-28 WO disclosed
WO-2010132601-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-11-18 WO disclosed